Rx pediculicide
This article was originally published in The Tan Sheet
Executive Summary
Summers Laboratories is actively enrolling patients in a Phase III clinical trial for its patented lice asphyxiator product, tentatively named Lice Choker, the company announces April 24. An NDA for sale of the product as an Rx drug will be filed in the fourth quarter of 2006. The product contains "a simple mixture of ingredients currently used in other dermatological medications and cosmetics" and will suffocate lice more successfully than olive oil and petroleum jelly, Summers maintains. According to studies, two 10-minute applications of the product one week apart effectively kill all lice, the company states, with one study showing a 100% effective kill rate. A recent article in the Journal of the American Academy of Dermatology said asphyxiating treatments should be further researched, given the increasing resistance of lice to OTC pyrethroid-based formulas (1"The Tan Sheet" April 17, 2006, p. 13)...
You may also be interested in...
Lice “Smothering” Agents Should Be Explored, Researchers Assert
Further research on topical agents that can asphyxiate lice should be conducted to enhance current treatment methods, according to a commentary published in the April issue of the Journal of the American Academy of Dermatology
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.